Drug review decisions
Last updated on January 19, 2026On this page:
- Drug review results search tool: Find out if a drug is under review, where it is in the review process, if and when PharmaCare decided to cover it, and the plans it is covered under
- Drug decision summaries: Drugs reviewed by PharmaCare, with a summary noting the reasons they were or were not covered
- Therapy and program reviews: Reviews of specific programs and conditions, plus supporting information such as drug decision summaries, clinical and pharmacoeconomic evidence reports, and Drug Benefit Council recommendations
Use this tool to search:
- All drugs reviewed by CDA (formerly CADTH) and submitted to the Ministry of Health for consideration
- All drug reviews completed by the Ministry since 2005
- Brand-name drugs currently under review by the Ministry and CDA (formerly CADTH), with results including:
- the drug's brand name, chemical name, and manufacturer
- the drug's indication (the condition it treats)
- the date the drug was submitted to the Ministry
- the date the drug was discussed by the Drug Benefit Council (DBC)
- whether the drug was reviewed by CDA
- the date CDA made its recommendation
- the drug's PharmaCare program status (e.g., under review, non-benefit)
- the date the Ministry made its decision
Generic drugs are not included.
To search for drugs not found with this search tool, try using the PharmaCare formulary search.
Go to the Drug review results search tool
Any column in this table can be alphabetically sorted. Drugs that have not been reviewed or that were reviewed before 2008 will not appear in this table.
| Generic name | Brand name | Indication | PharmaCare decision dates (yyyy/mm/dd) and summaries (PDF) |
|---|---|---|---|
| semaglutide | Wegovy® | As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with a body mass index (BMI) ≥ 27 kg/m2 and established cardiovascular disease (CVD), defined as myocardial infarction (MI), prior stroke, or peripheral artery disease (PAD) | 2025/12/18 |
| belumosudil | Rezurock® | For the treatment of patients aged 12 years and older with chronic graft-versus-host-disease (cGvHD) after failure of at least two prior lines of systemic therapy | 2025/12/17 |
| trofinetide | Daybue® | For the treatment of Rett syndrome (RTT) in adults and pediatric patients 2 years of age and older and weighing at least 9 kg | 2025/12/01 |
| burosumab | Crysvita® | For the treatment of X-linked hypophosphatemia (XLH) in adult patients | 2025/11/12 |
| maralixibat | Livmarli® | For the treatment of cholestatic pruritis in patients with Alagille syndrome (ALGS) | 2025/10/30 |
| etrasimod | Velsipity™ | Moderately to severely active ulcerative colitis (UC) in adults who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment | 2025/11/12 |
| ravulizumab | Ultomiris® | For the treatment of adult patients with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) | 2025/09/16 |
| insulin icodec | Awiqli® | For the once-weekly treatment of adults (≥18 years of age) with Type 2 diabetes mellitus (T2DM) to improve glycemic control | 2025/09/10 |
| edoxaban | generics |
|
2025/09/04 |
| tofacitinib | generics | For the treatment of adult patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA) | 2025/07/16 |
| bimekizumab | Bimzelx® | For the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately or are intolerant to conventional therapy | 2025/07/16 |
| bimekizumab | Bimzelx® | For the treatment of adult patients with active psoriatic arthritis (PsA), alone or in combination with a conventional disease modifying antirheumatic drug (cDMARD) | 2025/07/16 |
| upadacitinib | Rinvoq® | For the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response to a biologic disease modifying antirheumatic drug (bDMARD) or when use of those therapies is inadvisable | 2025/07/16 |
| belimumab | Benlysta™ | In addition to standard therapy, for the treatment of active lupus nephritis (LN) in adult patients | 2025/06/11 |
| anifrolumab | Saphnelo® | In addition to standard therapy, for the treatment of adult patients with active, autoantibody positive, systemic lupus erythematosus (SLE), whose disease activity cannot be controlled despite an oral corticosteroid (OCS) dose of ≥10 mg/day of prednisone or its equivalent | 2025/06/04 |
| inebilizumab | Uplizna® | As a monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive | 2025/05/28 |
| tocilizumab | Tyenne® | rheumatoid arthritis, giant cell arteritis, active polyarticular juvenile idiopathic arthritis, active systemic juvenile idiopathic arthritis, and neuromyelitis optica spectrum disorder | 2025/05/27 |
| maribavir | Livtencity™ | post-transplant cytomegalovirus (CMV) infection/disease | 2025/04/03 |
| infliximab | Ixifi® | rheumatoid arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, psoriatic arthritis and plaque psoriasis | 2025/04/01 |
| palovarotene | Sohonos™ | reducing the formation of heterotopic ossification (HO) in adults and children (females aged 8 years and older; males aged 10 years and older) with fibrodysplasia ossificans progressiva (FOP) | 2025/03/20 |
| selumetinib | Koselugo™ | pediatric patients aged two years and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PNs) | 2025/02/12 |
| brolucizumab | Beovu® | diabetic macular edema (DME) | 2025/02/11 |
| cariprazine | Vraylar® | schizophrenia in adults | 2025/02/04 |
| infliximab | Remsima™ SC | Crohn's disease (CD), ulcerative colitis (UC), and rheumatoid arthritis (RA) | 2025/01/21 |
| efgartimod alfa | Vyvgart® | acetylcholine receptor antibody positive (AChR-Ab+) generalize myasthenia gravis (gMG) adult patients whose symptoms persist despite adequate treatment with acetylcholinesterase inhibitors (AChEIs), corticosteroids (CSs), and/or non-steroidal immunosuppressants (NSISTs) | 2025/01/08 |
| vutrisiran | Amvuttra® | stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis | 2024/12/19 |
| somapacitan | Sogroya® | long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (Growth Hormone Deficiency, or GHD) | 2024/12/17 |
| tralokinumab | Adtralza® | moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and who had an adequate trial or are ineligible for each of the following therapies: phototherapy (where available) and off-label immunosuppressants. | 2024/12/17 |
| roflumilast | Zoryve™ | topical treatment of plaque psoriasis (PsO), including treatment of PsO in the intertriginous areas (skin folds), in patients 12 years of age and older | 2024/12/12 |
| drospirenone | Slynd® | conception control in adolescent and adult women | 2024/12/10 |
| abatacept (SQ) | Orencia® | rheumatoid arthritis | 2014/02/25 |
| mavacamten | Camzyos™ | symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adults patients | 2024/11/26 |
| abobotulinumtoxinA | Dysport Therapeutic™ | cervical dystonia (spasmodic torticollis) and focal spasticity | 2019/02/26 |
| abrocitinib | Cinibqo™ | moderate to severe atopic dermatitis | 2023/11/23 |
| avatrombopag | Doptelet® | thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) | 2024/11/07 |
| aclidinium | Tudorza™, Genuair™ | chronic obstructive pulmonary disease (COPD) | 2014/09/30 |
| aclidinium bromide-formoterol fumarate dehydrate | Duaklir™, Genuair® | chronic obstructive pulmonary disease (COPD) | 2016/04/05 |
| adalimumab | Humira® | difficult-to-treat Crohn's disease | 2008/09/09 |
| adalimumab | Humira® | juvenile idiopathic arthritis | 2014/02/25 |
| adalimumab | Humira® | ulcerative colitis | 2017/06/20 |
| adalimumab | Humira® | hidradenitis suppurativa (HS) | 2017/04/18 and 2018/03/06 |
| adalimumab | Abrilada®, Amgevita®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi™, Yuflyma™ | rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa for adults, and plaque psoriasis | 2021/04/07, 2021/09/30 and 2022/08/18 |
| adalimumab (biosimilars) | Abrilada®, Amgevita®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi™, Yuflyma™ | active non-infectious uveitis in patients aged 2 years and older | 2024/07/03 |
| adefovir | Hepsera® | chronic hepatitis B | 2018/11/27 |
| alemtuzumab | Lemtrada™ | relapsing-remitting multiple sclerosis (RRMS) | 2018/02/06 |
| alendronate and risedronate | Fosamax®, Actonel®, generics | primary prevention of osteoporotic bone fractures | 2023/01/17 |
| alirocumab | Praluent™ | treatment of high-risk adult patients who have had prior cardiovascular (CV) events and require additional lowering of low density lipoprotein cholesterol (LDL-C) | 2020/01/28 |
| alogliptin | Nesina™ | type 2 diabetes mellitus | 2015/05/05 |
| alogliptin-metformin | Kazano™ | type 2 diabetes mellitus | 2015/05/05 |
| amifampridine | Ruzurgi® | Lambert-Eaton myasthenic syndrome (LEMS) | 2023/03/28 |
| amifampridine phosphate | Firdapse® | Lambert-Eaton Myasthenic Syndrome (LEMS) | 2023/09/07 |
| apixaban | Eliquis® | stroke prophylaxis in atrial fibrillation | 2013/09/19 |
| apixaban | Eliquis® | prevention of venous thromboembolic events | 2013/12/10 |
| apixaban | Eliquis® | thromboembolic events (venous), treatment and prevention of recurrence | 2016/04/05 |
| apomorphine | Movapo™ | advanced Parkinson’s disease | 2019/11/26 |
| apomorphine hydrochloride | Kynmobi® | “OFF” episodes in adults with Parkinson’s disease | 2022/06/27 |
| apremilast | Otezla® | moderate to severe plaque psoriasis | 2017/10/10 |
| apremilast | Otezla® | psoriatic arthritis | 2017/10/10 |
| aprepitant | Emend® | prevention of vomiting in patients with cancer | 2010/03/16 |
| aripiprazole | Abilify® | major depressive disorder (MDD) | 2015/04/14 |
| aripiprazole monohydrate | Abilify Maintena™ | schizophrenia | 2015/08/11 |
| asunaprevir | Sunvepra™ | chronic hepatitis C (CHC) | 2017/03/21 |
| atogepant | Qulipta® | prevention of episodic and chronic migraine in adults | 2024/12/03 |
| atomoxetine | Strattera® and generics | attention deficit hyperactivity disorder (ADHD) | 2017/04/18 and 2020/06/09 |
| avacopan | Tavneos® | for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-AV) in combination with standard background therapy including glucocorticoids | 2024/02/27 |
| avalglucosidase alfa | Nexviazyme™ | late-onset Pompe disease (LOPD) | 2023/10/25 |
| azelastine hydrochloride – fluticasone propionate | Dymista® | moderate to severe seasonal allergic rhinitis and associated ocular symptoms | 2015/09/29 |
| azilsartan | Edarbi | hypertension, essential | 2014/07/29 |
| azilsartan | Edarbyclor | hypertension, essential | 2014/07/29 |
| baricitinib | Olumiant™ | moderate to severe rheumatoid arthritis in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drug (DMARD) | 2020/11/17 |
| belimumab | Benlysta® | reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) | 2021/06/06 |
| benralizumab | Fasenra® | severe eosinophilic asthma | 2020/04/01 |
| berotralstat | Orladeyo® | hereditary agioedema (HAE) | 2024/11/07 |
| bimekizumab | Bimzelx™ | moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy | 2023/01/31 |
| boceprevir | Victrelis™ | HIV/hepatitis C | 2013/10/10 |
| brexpiprazole | Rexulti® | schizophrenia | 2019/12/17 |
| brinzolamide-brimonidine | Simbrinza® | glaucoma and ocular hypertension | 2015/10/27 |
| brivaracetam | Brivlera® | epilepsy, partial-onset seizures | 2021/09/03 |
| brodulamab | Siliq™ | plaque psoriasis | 2018/11/27 |
| brolucizumab | Beovu® | neovascular (wet) age-related macular degeneration (nAMD) | 2022/06/22 |
| budesonide | Cortiment®MMX | induction of remission in patients with active, mild to moderate ulcerative colitis | 2017/06/13 |
| budesonide | Jorveza™ | induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE) | 2022/08/18 |
| budesonide-glycopyrronium-formoterol | Breztri® Aerosphere® | Chronic Obstructive Pulmonary Disease (COPD) | 2022/11/01 |
| buprenorphine extended release | Sublocade™ | opioid use disorder | 2020/04/30 |
| buprenorphine-naloxone | Suboxone® | opioid drug dependence in adults | 2015/11/13 |
| buprenorphine hydrochloride | Probuphine™ | management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support | 2020/02/25 |
| canagliflozin-metformin | Invokamet® | type 2 diabetes mellitus (T2DM) | 2022/0/18 |
| canakinumab | Ilaris® | active systemic juvenile idiopathic arthritis (sJIA) in patients aged two years and older | 2017/01/10 |
| cannabidiol | Epidiolex® | as adjunctive therapy for treatment of seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex |
2025/12/03 |
| caplacizumab | Cablivi® | powder for solution for intravenous or subcutaneous injection (11mg/vial) | 2023/05/26 |
| cenobamate | Xcopri™ | adjunctive therapy for management of partial-onset seizures (POS) in adults with epilepsy who are not satisfactorily controlled with conventional therapy | 2024/11/14 and 2025/05/20 |
| certolizumab pegol | Cimzia® | arthritis, psoriatic | 2016/02/19 |
| certolizumab pegol | Cimzia® | ankylosing spondylitis | 2016/02/19 |
| ciprofloxacin + dexamethasone (ear drops) | Ciprodex® | acute otitis media with otorrhea and otitis externa | 2009/01/16 and 2021/02/06 |
| cladribine | Mavenclad® | relapsing remitting multiple sclerosis (RRMS) | 2022/01/25 |
| clascoterone | Winlevi® | first-line prescription topical treatment of moderate and severe acne vulgaris in patients 12 years of age and older | 2025/11/19 |
| clopidogrel (1) | Plavix® | after drug-eluting stent insertion | 2008/02/18 |
| clopidogrel (2) | Plavix® | acute coronary syndrome | 2020/03/20 |
| clostridium botulinum neurotoxin type A, with complexing proteins | Xeomin® | muscle spasticity | 2010/06/15 |
| colchicine | Myinfla™ | add-on therapy to standard of care for the reduction of atherothrombotic events in patients who had a myocardial infarction | 2022/07/19 |
| colesevelam hydrochloride | Lodalis | hypercholesterolemia | 2013/06/13 |
| collagenase clostridium histolyticum | Xiaflex™ | Dupuytren’s contracture with a palpable cord | 2014/03/25 |
| continuous glucose monitoring (CGM) system | Dexcom G5® and Dexcom G6® | diabetes mellitus | 2021/06/01 |
| continuous glucose monitor (CGM) system | Guardian™ Sensor (3) glucose sensor, GuardianLink (3) transmitter, and Guardian Connect CGM system | diabetes mellitus | 2021/06/01 |
| continuous glucose monitor - transmitter | Dexcom G6® | diabetes mellitus | 2021/06/01 |
| continuous glucose monitoring (CGM) system | Dexcom G7® | diabetes mellitus | 2023/11/07 |
| crisaborole | Eucrisa™ | atopic dermatitis | 2020/01/14 |
| cyclosporine | Verkazia™ | severe vernal keratoconjunctivitis in children four years of age and older | 2021/03/23 |
| daclatasvir | Daklinza™ | chronic hepatitis C (CHC) | 2020/02/04 |
| dalbavancin hydrochloride | Xydalba® | treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) | 2024/09/17 |
| dapagliflozin | Forxiga® | heart failure with reduced ejection fraction (HFrEF) | 2022/01/11 |
| deferiprone | Ferriprox™ | transfusional iron overload due to thalassemia syndromes | 2016/10/25 |
| deferiprone | Ferriprox™ | treatment of patients with transfusional iron overload due to sickle cell disease (SCD) or other anemias | 2024/03/14 |
| delta-9-tetrahydrocannabinol + cannabidiol (1) | Sativex® | adjunctive neuropathic pain relief in multiple sclerosis | 2008/12/23 |
| delta-9-tetrahydrocannabinol + cannabidiol (2) | Sativex® | adjunctive pain relief in advanced cancer | 2008/12/23 |
| denosumab | Prolia® | men with osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy | 2017/02/14 |
| denosumab | Prolia® | women with breast cancer taking aromatase inhibitors without a documented fracture men with prostate cancer taking androgen deprivation therapy without a documented fracture |
2023/01/17 |
| denosumab | Prolia® | secondary prevention of osteoporotic fractures in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min | 2023/01/17 |
| denosumab | Xgeva® | prevention of skeletal-related events due to bone metastases from solid tumors | 2017/01/17 |
| denosumab | Jubbonti® and Wyost™ | Jubbonti: osteoporosis Wyost: hypercalcemia of malignancy (PharmaCare Plan P palliative care benefit) |
2024/08/29 |
| deucravacitinib | Sotyktu™ | treatment of adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy | 2024/07/25 |
| dexamethasone | Ozurdex® | diabetic macular edema | 2019/02/26 and 2023/08/17 |
| dextroamphetamine-amphetamine (mixed amphetamine salts) | Adderall XR® and generics | attention deficit hyperactivity disorder (ADHD) | 2017/04/18 and 2020/06/09 |
| difelikefalin | Korsuva® | treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis | 2024/04/30 |
| dimethyl fumerate | Tecfidera™ | multiple sclerosis, relapsing | 2014/06/24 |
| triheptanoin | Dojolvi™ | long-chain fatty acid oxidation disorders | 2023/05/23 |
| doxycycline | Apprilon® | rosacea | 2014/01/28 |
| dulaglutide | Trulicity® | type 2 diabetes | 2020/03/13 |
| duloxetine | generics | neuropathic pain | 2018/11/27 |
| dupilumab | Dupixent® | atopic dermatitis | 2019/01/22 and 2021/05/11 |
| dupilumab | Dupixent® | maintenance treatment for severe asthma | 2022/09/20 and 2023/10/17 |
| eculizumab | Soliris® | generalized myasthenia gravis (gMG) in adult patients | 2023/01/10 |
| eculizumab | Soliris® | hemolytic-uremic syndrome, atypical | 2014/01/14 |
| eculizumab | Soliris® | neuromyelitis optica spectrum disorder (NMOSD) | 2023/02/10 |
| edaravone | Radicava™ | amyotrophic lateral sclerosis (ALS) | 2020/08/19 |
| edoxaban | Lixiana® | stroke and blood clot prevention in atrial fibrillation; treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) | 2019/03/26 |
| efinaconazole | Jublia™ | fungal infection (onychomycosis) caused by certain fungi (Trichophyton species) | 2020/03/03 |
| elbasvir-grazoprevir | Zepatier® | chronic hepatitis C (CHC) | 2020/02/04 |
| elexacaftor/tezacaftor/ivacaftor | Trikafta® | treatment of cystic fibrosis in patients aged two years and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Trikafta based on clinical and/or in vitro data | 2024/11/06 |
| elosulfase alfa | Vimizim™ | mucopolysaccharidosis type IVA (MPS IVA or Morquio A syndrome) | 2015/09/22 |
| eltrombopag | Revolade® | chronic hepatitis C associated thrombocytopenia (low platelet counts) | 2015/07/14 |
| eluxadoline | Viberzi™ | irritable bowel syndrome | 2019/06/11 |
| empagliflozin | Jardiance™ | type 2 diabetes mellitus (T2DM) | 2019/05/27 |
| enoxaparin biosimilars | Inclunox®, Inclunox® HP, Noromby®, Noromby® HP, Redesca®, Redesca® HP | treatment and prophylaxis of venous thromboembolism (VTE) | 2022/03/22 |
| enoxaparin biosimilars | Elonox®, Elonox® HP | treatment and prophylaxis of venous thromboembolism (VTE) | 2023/06/01 |
| entecavir | Baraclude® | chronic hepatitis B | 2018/11/27 |
| eplerenone | Inspra® | heart failure, NYHA class II | 2014/11/18 |
| eptinezumab | Vyepti® | prevention of migraine in adults who have at least 4 migraine days per month | 2024/04/23 |
| erenumab | Aimovig® | prevention of chronic migraine in adults | 2022/03/29 |
| esketamine hydrochloride | Spravato® | major depressive disorder (MDD) in adults | 2021/08/03 |
| eslicarbazepine acetate | Afinitor® | epilepsy, partial-onset seizures | 2015/11/10 |
| estradiol | Imvexxy™ | treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy | 2024/05/14 |
| estradiol/progesterone | Bijuva™ | treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women with an intact uterus | 2023/06/06 |
| etanercept | Brenzys™; Erelzi™; Enbrel® | rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis | 2019/05/27 |
| etanercept | Erelzi™ | psoriatic arthritis | 2019/04/09 |
| etanercept | Brenzys™ | rheumatoid arthritis (RA), ankylosing spondylitis (AS), polyarticular juvenile idiopathic arthritis, psoriatic arthritis | 2017/06/18, 2021/02/18 (criteria expansion) |
| etanercept | Erelzi™ | rheumatoid arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis | 2017/11/14 |
| etanercept | Brenzys™, Erelzi™ | plaque psoriasis | 2021/04/07 |
| etanercept | Rymti® | moderately to severely active rheumatoid arthritis (RA), reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 to 17 years, reducing signs and symptoms of active ankylosing spondylitis (AS), inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA), and treatment of chronic moderate to severe plaque psoriasis (PsO) in adults | 2024/06/25 |
| etidronate (in combination with calcium carbonate) | Didrocal ACT-etidrocal |
prevention of fractures due to osteoporosis | 2019/02/19 |
| etonogestrel | Nexplanon® | prevention of pregnancy for up to three years | 2021/12/07 |
| everolimus (1) | Afinitor® | renal angiomyolipoma associated with tuberous sclerosis complex (TSC) | 2014/08/12 |
| everolimus (2) | Afinitor® | subependymal giant cell astrocytoma (SEGA), a brain tumour associated with a genetic condition called tuberous sclerosis complex (TSC) | 2015/07/28 |
| evolocumab | Repatha® | clinical artherosclerotic cardiovascular disease (ASCVD) | 2020/03/10 |
| evolocumab | Repatha® | heterozygous familial hypercholesterolemia | 2018/12/18 |
| exenatide | Byetta | type 2 diabetes mellitus (T2DM) | 2013/06/20 |
| elexacaftor/tezacaftor/ivacaftor | Trikafta® | cystic fibrosis in patients aged 2-5 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene | 2023/12/14 |
| ezetimibe | Ezetrol® | hypercholesterolemia | 2018/12/18 |
| ezetimibe | Ezetrol® | high cholesterol in patients with specific variants of NPC1L1 protein | 2007/09/27 |
| fampridine | Fampyra® | multiple sclerosis, improve walking ability | 2013/06/20 |
| fentanyl buccal/sublingual | Fentora® | management of breakthrough pain in adult cancer patients with difficulty swallowing or inadequate pain relief/intolerance/contraindication to morphine, oxycodone or hydromorphone | 2017/05/16 |
| fesoterodine fumarate | Toviaz® | overactive bladder | 2016/08/04 |
| fidaxomicin | Dificid® | Clostridium difficile infection | 2014/02/25 |
| filgrastim | Grastofil® | prevention/treatment of neutropenia | 2017/01/31 |
| filgrastim | Grastofil® | primary prophylaxis of febrile neutropenia in cancer patients receiving potentially curative myelosuppressive chemotherapy regimens where the risk of febrile neutropenia is ≥ 20% | 2018/10/16 |
| filgrastim | Grastofil® | pre-filled sterile solution for injection | 2017/01/31 |
| filgrastim | Nivestym™ | prevention/treatment of neutropenia | 2022/03/22 |
| filgrastim | Nypozi™ | prevention and treatment of neutropenia | 2024/05/14 |
| finerenone | Kerendia® | as an adjunct to standard of care therapy to delay progression of kidney disease and to reduce the risk of major adverse cardiovascular events (cardiovascular [CV] death, non-fatal myocardial infarction, non-fatal stroke) and hospitalization for heart failure in adults with chronic kidney disease (CKD) and type 2 diabetes (T2D) | 2024/02/27 |
| flash glucose monitoring (FGM) system | Freestyle® Libre and Freestyle Libre 2 | diabetes mellitus | 2021/06/01 |
| flash glucose monitoring (FGM) system | Freestyle® Libre 2 | diabetes mellitus | 2023/08/01 |
| fluorouracil and salicyclic acid | Actikerall™ | slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients | 2018/03/20 |
| fluticasone furoate | Arnuity™; Ellipta® | asthma | 2016/09/13 |
| fluticasone furoate-umeclidinium-vilanterol | Trelegy® Ellipta® | chronic obstructive pulmonary disease (COPD) | 2020/07/07 |
| fluticasone furoate-vilanterol | Breo®; Ellipta® | chronic obstructive pulmonary disease (COPD) | 2015/05/15 |
| fluticasone furoate-vilanterol | Breo®; Ellipta® | asthma | 2016/09/13 |
| fluticasone propionate | Aermony RespiClick™ | asthma in patients 12 years or older | 2020/02/11 and 2021/08/12 |
| fluticasone propionate/salmeterol xinafoate | Arbesda RespiClick™ | asthma in patients 12 years or older | 2020/02/11 |
| foslevodopa/foscarbidopa | Vyalev™ | treatment of advanced Parkinson’s Disease (aPD) | 2024/08/20 |
| fosfomycin | Monurol® | uncomplicated urinary tract infections | 2015/03/24 |
| fostamatinib | Tavalisse® | chronic immune thrombocytopenia (ITP) | 2023/01/31 |
| fremanezumab | Ajovy® | prevention of migraine in adults | 2022/03/29 |
| galcanezumab | Emgality® | prevention of migraine | 2023/04/11 |
| givosiran | Givlaari™ | treatment of acute hepatic porphyria (AHP) in adults | 2023/06/22 |
| glatiramer acetate | Copaxone® | relapsing remitting multiple sclerosis. | 2020/03/17 |
| glatiramer acetate | Glatect™ | relapsing remitting multiple sclerosis | 2018/11/27 |
| glecaprevir-pibrentasvir | Maviret™ | chronic hepatitis C | 2019/03/21, 2019/01/29, 2020/06/11 and 2021/04/14 |
| gliclazide | Diamicron® | type 2 diabetes | 2008/07/08 |
| glucagon nasal powder | Baqsimi™ | severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness prevents the ingestion of oral carbohydrates | 2022/04/05 |
| glycopyrrolate | Cuvposa™ | reduce drooling caused by certain health problems in patients 3 to 18 years of age | 2023/02/28 |
| glycopyrronium | Seebri® | chronic obstructive pulmonary disease (COPD) | 2013/09/19 |
| golimumab | Simponi® | ulcerative colitis | 2016/05/31 |
| golimumab | Simponi®; Intravenous (IV) | rheumatoid arthritis (RA) | 2016/05/31 |
| grass pollen allergen extract | Oralair™ | allergic rhinitis (grass pollen) | 2013/10/31 |
| guanfacine | Intuniv XR® | attention deficit hyperactivity disorder (ADHD) | 2017/04/18 |
| guselkumab | Tremfya® and Tremfya® One-Press™ | moderate to severe plaque psoriasis in adults | 2020/05/05 |
| guselkumab | Tremfya® and Tremfya® One-Press™ | for the treatment of adult patients with active psoriatic arthritis | 2023/11/28 |
| halobetasol propionate and tazarotene | Duobrii™ | plaque psoriasis | 2022/04/19 |
| icatibant | Firazyr® | angioedema | 2018/02/06 |
| icosapent ethyl | Vascepa® | prevention of cardiovascular events in statin-treated patients | 2023/07/06 |
| icosapent ethyl | Vascepa® | prevention of cardiovascular events in statin-treated patients | 2024/02/06 |
| imiquimod | Aldara® | actinic keratosis on the face or balding scalp | 2010/06/28 |
| inclisiran | Leqvio™ | lowering of low density lipoprotein cholesterol (LDL-C) | 2022/09/27 |
| incobotulinumtoxinA | Xeomin® | chronic sialorrhea associated with neurological disorders in adults | 2023/02/14 |
| indacaterol | Onbrez® | chronic obstructive pulmonary disease (COPD), maintenance bronchodilator treatment | 2013/05/30 |
| indacaterol-glycopyrronium | Ultibro®; Breezhaler® | chronic obstructive pulmonary disease (COPD) | 2015/06/02 |
| indacaterol-glycopyrronium-mometasone furoate | Enerzair® Breezhaler® | maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months | 2022/06/14 |
| indacaterol-mometasone furoate | Atectura® Breezhaler® | maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease | 2022/06/14 |
| infliximab | Avsola® | rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and plaque psoriasis | 2021/02/18 |
| infliximab | Inflectra®; Renflexis™; Remicade® | ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis | 2019/05/27 |
| infliximab | Inflectra™ | ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis | 2016/02/19 |
| infliximab | Inflectra®; Renflexis™ | Crohn’s disease and ulcerative colitis | 2019/09/05 |
| infliximab | Remsima™ SC | rheumatoid arthritis in adults | 2022/06/14 |
| ingenol mebutate | Picato® | keratosis, actinic | 2014/06/05 |
| inotersen | Tegsedi™ | polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR) | 2024/10/24 |
| insulin aspart | Kirsty® | type 1 & 2 diabetes mellitus | 2023/01/24 |
| insulin aspart and insulin lispro | Trurapi®; Admelog® | type 1 & 2 diabetes mellitus | 2021/11/30 |
| insulin degludec | Tresiba® | type 1 & 2 diabetes mellitus | 2008/06/12 |
| insulin degludec and liraglutide | Xultophy® | type 2 diabetes | 2020/03/13 |
| insulin glargine | Basaglar®; Lantus® | type 1 & 2 diabetes mellitus | 2019/05/27 |
| insulin glargine | Semglee® | type 1 or type 2 diabetes mellitus | 2023/05/25 |
| insulin glargine and lixisenatide | Soliqua™ | type 2 diabetes | 2020/03/13 |
| insulin glulisine | Apidra™ | type 1 & 2 diabetes mellitus | 2009/06/01 |
| interferon beta-1a | Rebif® | clinically isolated syndrome (MS) | 2014/03/25 |
| interferon beta-1b injection | Betaseron® | early treatment before a definite diagnosis of multiple sclerosis | 2008/07/08 |
| iron isomaltoside 1000 | Monoferric® | iron deficiency anemia (IDA) | 2021/10/06 |
| isavuconazole | Cresemba™ | invasive aspergillosis (IA) and invasive mucormycosis (IM) | 2021/02/23 |
| isotretinoin | Epuris™ | severe acne | 2013/10/10 |
| ivabradine | Lancora™ | heart failure | 2018/10/30 |
| ivacaftor | Kalydeco™ | cystic fibrosis (CF) in patients with G551D mutation | 2015/03/11 |
| ivermectin | Rosiver™ | inflammatory lesions of rosacea in adults 18 years of age and older | 2016/09/27 |
| ixekizumab | Taltz™ | ankylosing spondylitis | 2022/03/15 |
| ixekizumab | Taltz™ | psoriatic arthritis | 2019/05/27 |
| ixekizumab | Taltz™ | severe plaque psoriasis | 2018/03/06 |
| lamotrigine | Lamictal® and generics | bipolar disorder | 2019/11/12 |
| latanoprost | Monoprost® | reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension | 2020/01/28 |
| latanoprostene bunod | Vyzulta® | reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension | 2020/10/30 |
| lebrikizumab | Ebglyss™ | moderate-to-severe atopic dermatitis (AD) in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable | 2025/11/19 |
| ledipasvir-sofosbuvir | Harvoni™ | chronic hepatitis C (CHC) | 2020/02/04 |
| lemborexant | Dayvigo® | treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance | 2024/03/14 |
| letermovir | Prevymis™ | prophylaxis of cytomegalovirus (CMV) infection | 2021/05/18 |
| levodopa + carbidopa + entacapone | Stalevo® | hard-to-treat Parkinson’s disease | 2009/06/05 |
| levodopa-carbidopa | Duodopa® | advanced Parkinson's disease | 2020/12/10 |
| levofloxacin | Levaquin® | short-course airway infections | 2009/01/14 |
| levofloxacin | Quinsair | cystic fibrosis | 2018/10/16 |
| linagliptin; linagliptin-metformin | Trajenta®, Jentadueto™ | type 2 diabetes mellitus | 2014/08/05 |
| lipase-amylase-protease | Creon Minimicrospheres® 35 | pancreatic exocrine insufficiency (PEI) attribute to cystic fibrosis (CF), chronic pancreatitis (CP), or any other medically defined pancreatic disease that might require pancreatic enzyme therapy | 2021/08/19 |
| liraglutide | Saxenda® | adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients | 2022/04/26 |
| lisdexamfetamine | Vyvanse® | attention deficit hyperactivity disorder (ADHD) | 2017/04/18 and 2020/06/090 |
| lixisenatide | Adlyxine™ | type 2 diabetes mellitus | 2018/06/12 |
| lomitapide | Juxtapid™ | to reduce high cholesterol caused by homozygous familial hypercholesterolemia (HoFH) | 2015/06/23 |
| lovastatin + niacin | Advicor® | high cholesterol | 2008/03/03 |
| lumacaftor-ivacaftor | Orkambi | cystic fibrosis (CF) in patients with F508del mutation | 2017/03/21 |
| lumasiran | Oxlumo® | treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients | 2024/07/16 |
| lurasidone | Latuda™ | schizophrenia | 2013/09/19 and 2014/09/16 |
| lurasidone | Latuda™ | for the management of schizophrenia and for the acute management of depressive episodes associated with bipolar I disorder | 2024/03/07 |
| luspatercept | Reblozyl® | lyophilized powder for solution for subcutaneous injection | 2023/03/14 |
| luspatercept | Reblozyl® | lyophilized powder for solution for subcutaneous injection | 2023/03/14 |
| macitentan | Opsumit™ | pulmonary arterial hypertension | 2016/01/26 |
| macitentan-tadalafil | Opsynvi® | pulmonary arterial hypertension (PAH), in World Health Organization (WHO) Functional Class (FC) II or III patients | 2022/09/14 |
| mecasermin | Increlex® | The treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD) | 2023/04/27 |
| medroxyprogesterone acetate | Depo-Provera® | prevention of pregnancy and treatment of endometriosis | 2022/04/19 |
| mepolizumab | Nucala™ | severe eosinophilic asthma | 2019/10/29 |
| mepolizumab | Nucala™ | asthma | 2020/05/26 |
| mesalazine | Mezera™ | ulcerative colitis and ulcerative proctitis | 2019/02/26 and 2025/06/18 |
| methadone | Metadol-D® | opioid use disorder | 2019/03/26 |
| methylphenidate (extended-release) | Concerta® and generics | attention deficit hyperactivity disorder (ADHD) | 2017/04/18 and 2020/06/09 |
| methylphenidate (controlled-release) | Biphentin® | attention deficit hyperactivity disorder (ADHD) | 2017/04/18 |
| mifepristone and misoprostol | Mifegymiso® | medical termination of a developing intra-uterine pregnancy with a gestational age up to 49 days as measured from the first day of the last menstrual period (LMP) in a presumed 28-day cycle | 2017/07/11 |
| mirabegron | Myrbetriq® | overactive bladder | 2016/08/04 |
| mirikizumab | Omvoh® | adults patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a janus kinase (JAK)-inhibitor | 2024/11/19 |
| moxifloxacin | Avelox® | airway infections | 2009/01/15 |
| mycophenolate mofetil | Teva-Mycophenolate® | bullous pemphigoid and autoimmune hepatitis | 2019/11/26 |
| naltrexone hydrochloride and bupropion hydrochloride | Contrave® | chronic weight management in obese adults with a body mass index (BMI) of 30 kg/m2 or greater or overweight adults with a BMI of 27 kg/m2 or greater who have at least one weight-related condition | 2021/05/25 |
| natalizumab | Tysabri® | relapsing remitting multiple sclerosis | 2019/03/26 |
| nebivolol | Bystolic® | hypertension, essential | 2014/03/25 |
| netupitant-palonosetron | Akynzeo™ | prevention of chemotherapy-induced nausea and vomiting (CINV) in adult patients | 2019/11/26 |
| nintedanib | Ofev® | idiopathic pulmonary fibrosis (IPF) | 2018/02/06 |
| nintedanib | Ofev® | chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype also known as progressive fibrosing ILD (PF-ILD) or progressive pulmonary fibrosis (PPF) | 2022/06/07 |
| nirmatrelvir-ritonavir | Paxlovid™ | mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death | 2024/05/28 |
| nusinersen | Spinraza® | adult type 2 and type 3 spinal muscular atrophy (SMA) | 2022/12/15 |
| obeticholic acid | Ocaliva® | primary biliary cholangitis | 2018/10/30 |
| ocrelizumab | Ocrevus® | relapsing remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS) | 2020/08/20 |
| ocriplasmin | Jetrea® | symptomatic vitreomacular adhesion | 2015/01/27 |
| ofatumumab | Kesimpta™ | elapsing remitting multiple sclerosis (RRMS) | 2022/06/27 |
| omalizumab | Xolair® | chronic idiopathic urticarial | 2016/11/29 and 2020/04/28 |
| ombitasvir-paritaprevir-ritonavir and dasabuvir | Holkira™Pak | chronic hepatitis C (CHC) genotype 1 infection | 2015/07/28 |
| onabotulinumtoxinA | Botox® | prevention of headaches in adults with chronic migraine | 2014/11/18 |
| onabotulinumtoxinA | Botox® | overactive bladder | 2019/02/26 |
| onabotulinumtoxinA | Botox® | prophylaxis of headaches in adults with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) | 2022/03/29 |
| ospemifene | Osphena® | dyspareunia (pain with intercourse) and/or vaginal dryness, associated with of postmenopausal vulvovaginal atrophy | 2023/05/30 |
| oxybutynin (controlled-release) | Uromax® | overactive bladder | 2008/02/27 |
| ozanimod | Zeposia® | adult patients with the relapsing and remitting form of multiple sclerosis (RRMS) | 2022/07/26 |
| ozanimod | Zeposia® | for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic agent | 2024/01/16 |
| ozenoxacin | Ozenax™ | impetigo | 2019/04/09 |
| palonosetron hydrochloride | Aloxi® capsule | nausea and vomiting (chemotherapy induced) prevention | 2013/10/31 |
| palonosetron hydrochloride | Aloxi® injection | nausea and vomiting (chemotherapy induced) prevention | 2013/10/31 |
| pasireotide | Signifor® | treatment of adult patients with Cushing's disease for whom medical therapy is appropriate | 2015/09/01 |
| patiromer | Veltassa® | hyperkalemia in patients with chronic kidney disease stage 3-4 on Renin-Angiotensin Aldosterone System Inhibitors (RAASi) | 2022/07/19 |
| pegcetacoplan | Empaveli™ | treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor | 2024/03/06 |
| pegfilgrastim | Fulphila™ | decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs | 2020/02/11 |
| pegfilgrastim | Lapelga | decrease infection with febrile neutropenia for non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs | 2019/07/09 |
| pegfilgrastim | Nyvepria™ | decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs | 2022/05/10 |
| pegfilgrastim | Ziextenzo® | decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs | 2022/05/10 |
| peginterferon beta-1a | Plegridy | multiple sclerosis (MS), relapsing | 2016/08/04 |
| pegvisomant | Somavert® | last line of treatment for acromegaly | 2014/01/14 |
| perampanel | Fycompa™ | epilepsy, partial onset seizures | 2014/08/15 and 2020/09/24 |
| perindopril arginine-amlodipine | Viacoram® | essential hypertension | 2017/07/25 |
| pirfenidone | Esbriet™ | idiopathic pulmonary fibrosis (IPF) | 2014/01/14 |
| pitolisant hydrochloride | Wakix® | treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy | 2023/08/15 |
| prasugrel | generics | prevention of atherothrombotic events in patients with acute coronary syndrome | 2021/12/14 |
| prasterone | Intrarosa™ | postmenopausal vulvovaginal atrophy | 2023/05/30 |
| propiverine | Mictoryl® | overactive bladder (OAB) | 2018/03/20 |
| propranolol hydrochloride | Hemangiol™ | proliferating infantile hemangioma | 2019/01/29 |
| propylthiouracil | Halycil™ | medical management of hyperthyroidism; in conjunction with radioiodine to hasten recovery while awaiting the effects of radiation; control of thyrotoxicosis prior to surgery; management of a thyroid storm in addition to other therapeutic measures | 2022/05/31 |
| ramipril + hydrochlorothiazide | Altace HCT® | hypertension | 2008/12/17 |
| remdesivir | Veklury® | treatment of COVID-19 in both hospitalized and non-hospitalized patients | 2025/11/26 |
| ranolazine | Corzyna™ | add-on symptomatic treatment for inadequately controlled stable angina | 2022/02/01 |
| ravulizumab | Ultomiris® | atypical hemolytic uremic syndrome, to inhibit complement mediated thrombotic microangiopathy | 2023/09/22 |
| ravulizumab | Ultomiris® | treatment of adult patients with anti-acetylcholine receptor (AChR) anti-body positive generalized myasthenia gravis (gMG) | 2024/04/17 |
| reslizumab | Cinqair™ | add-on maintenance treatment for adults with severe eosinophilic asthma | 2020/04/28 |
| rifaximin | Zaxine® | hepatic encephalopathy | 2018/02/06 |
| riociguat | Adempas® | chronic thromboembolic pulmonary hypertension (CTEPH) | 2015/03/10 |
| riociguat | Adempas® | pulmonary arterial hypertension (PAH) | 2017/05/02 |
| risankizumab | Skyrizi® | moderate to severe plaque psoriasis in adults | 2020/05/05 |
| risankizumab | Skyrizi® | adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, or demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies | 2024/05/30 |
| risperidone | Perseris® | schizophrenia in adults | 2022/08/16 |
| rituximab | Rituxan® | relapsing remitting multiple sclerosis | 2018/11/27 |
| rituximab | Riximyo™ | severely active rheumatoid arthritis (RA), relapsing remitting multiple sclerosis (RRMS) | 2020/08/20 and 2021/08/19 |
| rituximab | Ruxience™ | severely active rheumatoid arthritis (RA), relapsing remitting multiple sclerosis (RRMS), the induction of remission in severely active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) | 2020/08/20 |
| rituximab | Truxima™ | severely active rheumatoid arthritis (RA), relapsing remitting multiple sclerosis (RRMS), the induction of remission in severely active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) | 2020/08/20 |
| rivaroxaban | Xarelto® | thromboembolic events (venous), pulmonary embolism (PE) | 2014//9/30 and 2020/04/01 |
| romosozumab | Evenity™ | for the treatment of osteoporosis in postmenopausal women at high risk for fractures | 2023/12/12 |
| rotigotine | Neupro® | Parkinson's disease | 2018/11/13 |
| ruxolitinib | Jakavi® | chronic graft-versus-host disease (cGvHD) in patients aged 12 years and older | 2023/11/23 |
| ruxolitinib | Jakavi® | acute graft-versus-host disease (cGvHD) in patients aged 12 years and older | 2023/11/23 |
| sacubitril-valsartan | Entresto™ | heart failure | 2018/05/06 and 2020/10/05 |
| sarilumab | Kevzara | rheumatoid arthritis | 2017/10/17 and 2020/06/30 |
| satralizumab | Enspryng® | for the treatment of neuromyelitis optica spectrum disorders (NMOSD) | 2023/11/01 |
| saxagliptin; saxagliptin-metformin | Onglyza®, Komboglyze™ | type 2 diabetes mellitus | 2014/08/05 |
| sebelipase alfa | Kanuma® | lysosomal acid lipase deficiency (LAL-D) | 2023/04/05 |
| secukinumab | Cosentyx® | psoriasis, moderate to severe plaque | 2016/07/28 |
| secukinumab | Cosentyx® | psoriatic arthritis | 2018/04/24 |
| secukinumab | Cosentyx® | hidradenitis suppurativa | 2025/08/13 |
| setmelanotide | Imcivree® | weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS) | 2025/07/29 |
| selexipag | Uptravi® | pulmonary arterial hypertension | 2018/10/30 |
| semaglutide | Ozempic® | type 2 diabetes mellitus | 2020/12/15 |
| semaglutide | Rybelsus® | type 2 diabetes mellitus | 2023/01/31 |
| simeprevir | Galexos™ | chronic hepatitis C (CHC) genotype 1 infection | 2014/10/28 |
| siponimod | Mayzent™ | secondary progressive multiple sclerosis (SPMS) | 2022/01/25 |
| sitagliptin; sitagliptin-metformin | Januvia®, Janumet®, Janumet® XR | type 2 diabetes mellitus | 2014/08/05 |
| sodium phenylbutyrate and ursodoxicoltaurine (PB-TURSO) | Albrioza™ | amyotrophic lateral sclerosis (ALS) | 2024/07/19 (delisting) and 2023/07/19 |
| sodium zirconium cyclosilicate | Lokelma™ | hyperkalemia in adults | 2020/08/18 |
| sofosbuvir | Sovaldi® | chronic hepatitis C (CHC) | 2020/02/04 |
| sofosbuvir-velpatasvir | Epclusa™ | chronic hepatitis C (CHC) | 2020/02/04 |
| sofosbuvir-velpatasvir-voxilaprevir | Vosevi™ | chronic hepatitis C (CHC) | 2020/02/04 |
| somatrogon | Ngenla™ | long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (known as, growth hormone deficiency) | 2023/05/02 |
| somatropin | Genotropin® | growth hormone deficiency, adults | 2014/08/05 |
| somatropin | Genotropin® | growth hormone deficiency, pediatrics | 2014/08/05 |
| somatropin | Genotropin® | growth hormone deficiency, Turner syndrome | 2014/08/05 |
| somatropin | Omnitrope® | growth hormone deficiency or chronic renal insufficiency, pediatric | 2018/04/10 |
| stiripentol | Diacomit™ | severe myoclonic epilepsy in infancy (Dravet syndrome) | 2015/07/07 |
| tapentadol | Nucynta® | severe pain | 2019/05/22 |
| teduglutide | Revestive® | short bowel syndrome (SBS) | 2017/08/15 |
| telaprevir | Incivek® | chronic hepatitis C virus infection in patients co-infected with HIV | 2013/10/10 |
| telbivudine | Sebivo® | chronic hepatitis B infection in patients with liver disease | 2008/03/27 |
| tenofovir alafenamide fumarate | Vemlidy™ | chronic hepatitis B | 2018/12/18, 2025/12/03 |
| tenofovir disoproxil fumarate | Viread® | chronic hepatitis B | 2018/11/27 |
| teriflunomide | Aubagio™ | relapsing-remitting multiple sclerosis (RRMS) | 2014/12/09 |
| tesamorelin | Egrifta® | excess visceral adipose tissue (VAT) in treatment-experienced adult human immunodeficiency virus (HIV)-infected patients with lipodystrophy | 2016/12/13 |
| tezepelumab | Tezspire™ | as an add-on maintenance treatment in adults and adolescents 12 years of age and older with severe asthma | 2023/12/14 |
| ticagrelor | Brilinta® | in combination with low-dose acetylsalicylic acid (ASA) for the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI occurring at least one year ago) and a high-risk of developing an atherothrombotic event | 2017/09/05 |
| tildrakizumab | Ilumya™ | moderate-to-severe plaque psoriasis in adult patients | 2022/02/22 |
| tinzaparin | Innohep® | venous thromboembolism (VTE) associated with cancer | 2017/02/14 |
| tiotropium bromide | Spiriva® Respimat® | chronic obstructive pulmonary disease (COPD) | 2016/04/05 |
| tiotropium-olodaterol | Inspiolto™ Respimat® | chronic obstructive pulmonary disease (COPD) | 2016/04/05 |
| tocilizumab | Actemra® | moderate to severely active polyarticular juvenile idiopathic arthritis (pJIA) | 2014/12/09 |
| tocilizumab | Actemra® | rheumatoid arthritis | 2016/02/19 |
| tocilizumab | Actemra® | giant cell arteritis | 2019/03/12 |
| tofacitinib | Xeljanz™ | rheumatoid arthritis (RA) | 2017/01.31, 2020/11/17 |
| tofacitinib | Xeljanz™ | ulcerative colitis (UC) | 2020/11/17 |
| tolvaptan | Samsca® | hyponatremia, non-hypovolemic | 2013/08/15 |
| tralokinumab | Adtralza® | moderate-to-severe atopic dermatitis | 2022/12/13 |
| travoprost ophthalmic solution | Izba™ | open-angle glaucoma | 2018/05/29 |
| triamcinolone hexacetonide | N/A | symptoms of subacute and chronic inflammatory joint diseases in adults and adolescents | 2021/11/16 |
| trientine | Mar-Trientine | Wilson's disease | 2022/05/17 |
| trientine | Waymade-Trientine | Wilson's disease | 2022/10/25 |
| ulipristal acetate | Fibristal® | uterine fibroids | 2018/10/02 |
| umeclidinium | Incruse™ Ellipta® | chronic obstructive pulmonary disease (COPD) | 2016/03/15 |
| umeclidinium-vilanterol | Anoro™ Ellipta™ | chronic obstructive pulmonary disease (COPD) | 2015/08/11 |
| upadacitinib | Rinvoq® | moderate to severe active rheumatoid arthritis | 2022/11/29 |
| upadacitinib | Rinvoq® | moderate to severe psoriatic arthritis (PsA) | 2022/11/29 |
| upadacitinib | Rinvoq® | moderate to severe atopic dermatitis | 2023/11/23 |
| upadacitinib | Rinvoq® | treatment of adult patients with moderately to severely active Crohn's disease (CD) | 2024/09/17 |
| upadacitinib | Rinvoq® | treatment of moderately to severely active ulcerative colitis (US) in adults who have demonstrated prior treatment failure, i.e., an inadequate response to, loss of response to, or intolerance to at least one of conventional and/or biologic therapy | 2024/10/03 |
| ustekinumab | Stelara® | moderate to severe psoriatic arthritis (PsA) | 2015/05/26 |
| ustekinumab | Stelara® | Crohn's disease | 2019/08/27 |
| ustekinumab | Stelara® | moderate to severe active ulcerative colitis in adults | 2023/01/17 |
| ustekinumab | Jamteki™ | treatment of adult patients with active psoriatic arthritis and for the treatment of chronic moderate to severe plaque psoriasis in adult patients | 2024/05/30 |
| ustekinumab | Wezlana™ and Steqeyma® | plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis (Wezlana) plaque psoriasis, psoriatic arthritis, and Crohn's disease (Steqeyma) |
2024/09/17 |
| vancomycin oral | generics | Clostridium difficile infection | 2019/12/18 |
| vedolizumab | Entyvio™ | Crohn's disease | 2017/05/02 |
| vedolizumab | Entyvio™ | ulcerative colitis | 2017/05/02 |
| vedolizumab | Entyvio™ | Crohn's disease, ulcerative colitis | 2022/04/12 |
| vericiguat | Verquvo® | treatment of symptomatic chronic heart failure (HF) in adult patients with reduced ejection fraction who are stabilized after a recent HF decompensation event requiring hospitalization and/or intravenous diuretic therapy. Verquvo should be taken in combination with other standard of care therapies for HF. | 2024/10/15 |
| voretigene neparvovec | Luxturna® | vision loss due to inherited retinal dystrophy (IRD) caused by confirmed biallelic RPE65 mutations | 2023/02/28 |
| vortioxetine | Trintellix™ | major depressive disorder (MDD) | 2021/07/06 |
| Subject of review | Drugs included in review | Date | Supporting information and documents |
|---|---|---|---|
| Alzheimer’s disease |
|
April 2016 | Alzheimer's drug therapy review reports and DBC recommendation |
| Attention deficit hyperactivity disorder (ADHD) |
|
April 2017 |
Attention Deficit Hyperactivity Disorder (ADHD) Drug Therapy Review Reports |
| Cancer-associated thrombosis (CAT) | LMWH (originator and biosimilar):
|
March 22, 2022 | Cancer-associated thrombosis therapeutic review (PDF, 2.04MB) |
| Chronic obstructive pulmonary disease (COPD) | All drug classes covered under COPD:
|
July 2020 |
|
| Multiple sclerosis (relapsing remitting) |
|
January 25, 2022 | |
| Overactive bladder (OAB) |
|
August 2016 | |
| Reference Drug Program | All drugs covered under the Reference Drug Program:
|
June 2016 | RDP review reports and DBC recommendation |
